Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.55 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.55 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | ATR | Q13535 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3111821 | 0.87 | CHRNB2 (0.56) | MAPK8KDM4ELMNACHRNB2CHRNB4 | |
| SCHEMBL27697741 | 0.86 | KDM4E (0.57) | MAPK8KDM4ELMNACHRNB2CHRNB4 | |
| SCHEMBL5032590 | 0.84 | NR3C2 (0.57) | MAPK8CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL6361201 | 0.84 | CHRNB2 (0.53) | MAPK8CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL30106114 | 0.83 | KDM4E (0.58) | MAPK8KDM4ELMNACHRNB2CHRNB4 | |
| SCHEMBL821844 | 0.82 | KDM4E (0.71) | MAPK8KDM4ELMNASMN1; SMN2RAB9A | |
| SCHEMBL4171284 | 0.81 | CHRNB2 (0.51) | MAPK8CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL91504 | 0.81 | CHRNB2 (0.54) | LMNACHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL10083508 | 0.81 | CHRNB2 (0.51) | MAPK8CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL10082485 | 0.80 | CHRNB2 (0.50) | MAPK8CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10927106-B2 | Benzothiazole derivatives as DYRK1 inhibitors | PHARMASUM THERAPEUTICS AS (NO) | 2021-02-23 | — | — | US | disclosed |
| US-20180086750-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LIMITED (GB) | 2018-03-29 | — | — | US | disclosed |
| US-9586951-B2 | Morpholine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2016-06-16 | — | — | US | disclosed |
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| WO-2010086646-A1 | SCRIPTAID ISOSTERES AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LIMITED (GB) | 2010-08-05 | — | — | WO | disclosed |
| WO-2009141659-A1 | DEPSIPEPTIDES AND THEIR THERAPEUTIC USE | KARUS THERAPEUTICS LIMITED (GB) | 2009-11-26 | — | — | WO | disclosed |
| US-7557213-B2 | Substituted quinolones and methods of use | CHEMOCENTRYX, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-20070167443-A1 | Substituted quinolones and methods of use | CHEMOCENTRYX, INC. (US) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927106-B2 | Benzothiazole derivatives as DYRK1 inhibitors | DYRK1A, DYRK1B, PDK2 | MAPK8 1163/4885KDM4E 984/4885LMNA 4785/4885 |
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | MAPK8 253/4885KDM4E 2722/4885LMNA 3593/4885 |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | PRMT7, RBBP7, RER1 | MAPK8 307/4885KDM4E 2666/4885LMNA 2540/4885 |
| US-20070167443-A1 | Substituted quinolones and methods of use | TOP2A, NQO2, TOP2B | MAPK8 4113/4885KDM4E 2670/4885LMNA 713/4885 |
| US-20180086750-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY | HDAC1, HDAC5, HDAC7 | MAPK8 2379/4885KDM4E 128/4885LMNA 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.